$CING

Hargroves Thomas Jeffrey purchased $490K of CING (indirect holdings)

Hargroves Thomas Jeffrey purchased 97,276 indirectly-held shares of Cingulate Inc. (CING) at $5.04 ($0.49M total) on 2026-02-13.

Original reporting
SEC EDGAR · Hargroves Thomas Jeffrey
Published Jun 8, 2026, 11:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CING
Bullish
medium confidence
Mentioned
$CING
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CINGBullishLow
01

Why it matters

Traders may treat the buy as a sentiment datapoint, but it does not introduce new operational or financial information about Cingulate.

02

Market read

A director’s disclosed open-market buy of ~$490k worth of Cingulate shares may slightly improve sentiment, but lacks fundamental catalysts.

03

What to watch

The transaction date (2026-02-13) precedes the filing by months, so the market may have already priced any related information; also, indirect ownership details may reduce interpretability.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-08; transaction dated 2026-02-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Cingulate Inc., showing a director’s open-market purchase.

Company-level read

Ticker impact

$CINGBullishMedium confidence
Context

Director Hargroves Jeffrey bought 97,276 shares of Cingulate at $5.04/share via an open-market purchase disclosed on Form 4.

Expected impact

Low-to-moderate near-term support possible, but no clear directional move implied by the disclosure alone.

Evidence & confidence

This is a routine SEC Form 4 insider buy with disclosed size/value, but it does not include new company fundamentals (no guidance, trial, deal, or regulatory action).

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity planning, or pre-existing intent; without a 10b5-1 plan and with an older trade date, follow-through may be limited.

Key entities

  • Cingulate Inc.

    Company whose shares were purchased by a director, disclosed via SEC Form 4.

  • Hargroves Thomas Jeffrey

    Director who reported an open-market purchase of Cingulate shares.

Related articles

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show